2006 proposed fee schedule - American Society of Clinical Oncology

347
TABLE 37--Impact of Proposed Changes in Payments to Hospital
Based and Independent ESRD Facilities
(Includes Drug and Composite Rate Payments)
[Percent Change in Total Payments to ESRD Facilities
(Both Program and Beneficiaries)]
1
2
Number
Of Facilities
3
Number of
Dialysis
Treatments
(in millions)
4
Effect of
Changes
in Wage
Index 1/
5
Effect of
Changes
in Drug
Payments 2/
6
Overall
Effect
3/
All 4,293 29.5 0.0 1.2 0.5
Independent 3,716 26.1 -0.1 1.2 0.4
Hospital Based 577 3.3 1.3 1.0 1.2
Size
Small < than 5000
treatments per year
Medium 5000 to 9999
treatments per year
Large > than 10000
treatments per year
1,714 4.9 -0.5 1.1 0.1
1,724 12.4 0.1 1.3 0.6
855 12.1 0.2 1.2 0.6
Type of Ownership
Profit 3,388 23.8 -0.2 1.2 0.4
Nonprofit 896 5.6 1.0 1.1 1.0
Rural 1,189 6.0 -0.6 1.1 0.1
Urban 3,104 23.5 0.2 1.2 0.6
Region
New England 143 1.1 3.7 1.6 2.9
Middle Atlantic 521 3.9 2.1 1.5 1.9
East North Central 651 4.6 -1.9 0.9 -0.8
West North Central 333 1.6 -0.9 1.0 -0.2
South Atlantic 975 6.8 -0.3 1.2 0.4
East South Central 342 2.2 -1.6 1.1 -0.4
West South Central 585 4.1 -1.3 1.1 -0.3
Mountain 226 1.3 -0.6 1.1 0.0
Pacific 486 3.7 2.6 1.5 2.2
Puerto Rico 31 0.3 -1.6 0.7 -0.7
1. This column shows the effect of wage changes to composite rate payments to ESRD providers. Composite rate
payments computed using the current wage index are compared to composite rate payments using the proposed wage
index changes.
2. This column shows the effect of the changes in drug payments to ESRD providers. These include proposed changes
In payment for separately billable drugs (2006 ASP+6) and the 8.9% drug add-on compared to current payment for
separately billable drugs (2005 AAP) and the current 8.7 percent drug add-on.